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We review mechanisms that regulate production of glucose by the liver, focusing on areas of budding
consensus, and endeavoring to provide a candid assessment of lingering controversies. We also attempt
to reconcile data from tracer studies in humans and large animals with the growing compilation of mouse
knockouts that display changes in glucose production. A clinical hallmark of diabetes, excessive glucose
production remains key to its treatment. Hence, we attempt to integrate emerging pathways into the broader
goal to rejuvenate the staid antidiabetic pharmacopeia.Introduction
Hepatic glucose production (HGP) is a key physiological process
that becomes altered in diabetic patients (Bogardus et al., 1984)
and represents themain target of the antihyperglycemic effect of
biguanides (Stumvoll et al., 1995). The combination of tracer and
spectroscopy methods in humans, selective catheterization of
portal and hepatic veins in dogs during tracer studies, condi-
tional knockouts and metabolic phenotyping in mice, and
NMR-based flux analysis in perfused liver and primary hepato-
cytes has yielded a wealth of information on mechanisms
controlling HGP. However, these investigations appear to occur
in tangential, if not parallel, universes, leading to often-conflicting
claims. The purpose of this review is to integrate this knowledge
by critically analyzing the extent to which different pathways
meet exacting genetic, cellular biological, and integrated physi-
ological criteria across different experimental models.
Features of HGP In Vivo, in the Perfused Liver,
and in Cultured Cells
Classic work by Exton and Park established that key features of
HGP can be reproduced in isolated liver (Exton and Park, 1967).
This work demonstrated that hormonal regulation of HGP is (1)
rapid, occurring within seconds of exposing the organ to
glucagon or insulin, (2) sensitive, as either hormone is effective
at subpicomolar concentrations, and (3) independent of
ongoing protein synthesis. The forgotten implications of these
landmark observations are that putative physiologic regulators
of HGP ought to be regulated at low hormone concentrations
by posttranslational modifications of existing signaling
complexes and by substrate flux, rather than by de novo gene
transcription.
In the 1980s, work in rodents and in cultured hepatocytes
conclusively demonstrated that, in addition to substrate flux,
insulin and glucagon also regulate expression of the rate-limiting
enzymes of glycogenolysis (the catalytic subunit of glucose-6-
phosphatase, encoded by G6pc) and gluconeogenesis (the
cytosolic phosphenolpyruvate carboxykinase, encoded by
Pck1). This work emphasized the role of cAMP- and insulin-
responsive transcription factors (O’Brien and Granner, 1996).
The unintended consequence of this landmark research wasthat regulation of gene transcription and HGP are all too often
conflated into a single process, with recurring interpretive
errors.
Tracerstudies indogshavedefinedhormonal regulationofHGP
indetail. As in the isolated rodent liver,HGP is exquisitely sensitive
to glucagon and insulin. Glucagon sets the basal tone, but insulin
trumps glucagon at any concentration—just as it does in vitro.
Both hormones affect primarily glycogenolysis by reciprocal
changes of glycogen synthase and glycogen phosphorylase
and by modulating glycolysis through glucokinase, fructose-
bisphosphatase and pyruvate kinase (see below) (Cherrington,
1999). Hormonal regulation of gluconeogenesis has proven diffi-
cult to demonstrate. Acute elevations of insulin in the physiologic
range have a transient effect on gluconeogenesis (Ramnanan
et al., 2010), whereas high insulin concentrations are required to
bring about persistent changes (Edgerton et al., 2009). Inhibition
of gluconeogenesis by insulin parallels its effect to lower free fatty
acids (FFAs) and lactate, consistent with a bimodal mechanism:
direct stimulation of glycolysis and glycogen synthesis, and
indirect inhibition through decreased gluconeogenic precurors
(Bergman and Ader, 2000). The Cherrington group also made
a commendable attempt to link flux data with signaling events,
as will be seen below (Ramnanan et al., 2010).
Physical exercise, by virtue of its combined actions on stress
and glucoregulatory hormones, as well as tissue glycogen levels,
is a potent regulator of HGP (Holloszy and Kohrt, 1996).
HGP and Diabetes
Unlike muscle and adipose insulin resistance, which antedate
hyperglycemia by years and remain relatively stable throughout
the course of the disease (Weyer et al., 1999), the rise of HGP
occurs ‘‘late’’ in the natural history of diabetes, but appears to
worsen progressively, and to become refractory to treatment
(Monnier et al., 2007). In type 2 diabetes, HGP is higher in the
postabsorptive state, and fails to be properly suppressed by
insulin, resulting primarily from excessive gluconeogenesis,
rather than glycogenolysis (Rizza, 2010). As HGP is inversely
correlated to insulin levels (Bogardus et al., 1984), its increase
probably reflects asmuch the plight of the b cell as it does a dete-
rioration of hepatic insulin action.Cell Metabolism 14, July 6, 2011 ª2011 Elsevier Inc. 9
Figure 1. Direct and Ondirect control of HGP
The liver integrates cell-autonomous and cell-nonautonomous mechanisms to control glucose release into the bloodstream. The role of altered glucagon-
to-insulin ratios in HGP of type 2 diabetics remains unsettled and of potential therapeutic import. Classicmechanisms of indirect control of HGP include release of
gluconeogenic precursors fromadipose tissue andmuscle (FFAs, glycerol, amino acids), adipocytokines (leptin, adiponectin, resistin), neuronal control—possibly
mediated through the vagus nerve. In addition, intrahepatic fat plays an important role in promoting HGP, possibly through accumulation of complex
phospholipids. Finally, intrahepatic accumulation of resident macrophages has in recent years taken center stage as a potential mechanism of insulin resistance,
leading to lipid accumulation and increased HGP.
Cell Metabolism
ReviewSeveral factors contribute to elevated gluconeogenesis in
diabetes: (1) increased supply of glucogenic precursors to the
liver (glycerol, amino acids, FFAs), (2) increased liver lipid
content, (3) cytokines and adipokines, (4) altered glucagon-
to-insulin ratios, (5) in rodents, vagal control originating in the
hypothalamus, and (6) decreased insulin receptor signaling in
hepatocytes (Figure 1).
Inhibition of gluconeogenesis by insulin in humans remains
disputed. The balance of the evidence is consistent with a small
effect that requires high insulin concentrations, and is possibly
secondary to decreased FFAs (Gastaldelli et al., 2001; Petersen
et al., 1998). Equally controversial is the role of glucagon in the
increased HGP of diabetes. Strong cases can be made for and
against a dominant role of glucagon in driving HGP (Raju and
Cryer, 2005).Wewould like to suggest that the effect of glucagon
on HGP is secondary to insulin resistance for three reasons.
First, insulin trumps glucagon at any concentration to inhibit
HGP, making it unlikely that hyperglucagonemia itself would be
sufficient to raise HGP, in the absence of insulin resistance.
Second, somatostatin has a biphasic effect on HGP to initially
inhibit it, then to stimulate it (Sherwin et al., 1976), indicating
that glucagon may not be necessary for the development of
hyperglycemia, and hence assigning a primary role to insulin.
Third, glucagon trumps insulin in supressing hepatic de novo
lipogenesis. Thus, even at concentrations that may not override
the effect of insulin on HGP, glucagon ought to prevent liver lipid
abnormalities. The fact that it doesn’t provides further evidence10 Cell Metabolism 14, July 6, 2011 ª2011 Elsevier Inc.that insulin resistance is the main driver of hepatic metabolic
abnormalities in type 2 diabetes.
The roles of adipokines, liver fat, and neural control in driving
HGP are reviewed below.
Regulation of HGP through Substrate Flux
Glycogen Synthase and Phosphorylase
The rapid onset of hormone action on HGP is likely indepen-
dent of gene transcription. The opposing effects of insulin
and glucagon on HGP pivot around their actions on glycogen
synthase and phosphorylase. By activating the former, insulin
favors glycogen deposition; glucagon activates the latter, re-
sulting in glycogenolysis. It should be emphasized that
increased glycogenolysis doesn’t necessarily increase HGP,
owing to glucose cycling (Petersen et al., 1998). Synthase acti-
vation by insulin involves phosphorylation at multiple sites and
allosteric binding of glucose-6-phosphate (Roach, 2002).
Phosphorylase is rate limiting for glycogenolysis and is oppo-
sitely regulated by covalent modifications, through PKA and
phosphorylase kinase, and allosterically by its product
glucose-6-phosphate. Demonstration that insulin inhibits
phosphorylase by covalent modifications is elusive. In euglyce-
mia, insulin paradoxically increases phosphorylase activity,
shunting glucose to glycogen cycling. Phosphorylase inhi-
bition by insulin is observed under hyperglycemic conditions,
suggesting a role for elevated glucose-6-phosphate levels in
this process (Petersen et al., 1998). Efforts to leverage
Figure 2. Hormonal and Nutrient Pathways of HGP Regulation in Hepatocytes
Some of the main signaling pathways reviewed in this article are summarized. Insulin, glucagon, and glucocorticoids remain the central regulators of HGP. Their
transcriptional effects are mediated through the Akt/Foxo and possibly Crtc2 pathways. AMPK, by virtue of its energy-sensing role, is likely to participate in
several of these processes, but its upstream regulators and downstream targets are elusive. Bile acids have profound effects on HGP through complex and
redundant mechanisms. Cytokines released from a variety of sources (fat cells, circulating as well as resident macrophages) also affect HGP and are likely to
impair insulin sensitivity. A second level of transcriptional integration is provided by cofactors such as Sirt1, Clock genes, Src1-3. Their hormonal regulation is
unknown at present. But transcriptional effects account only for part of HGP regulation. Direct control over enzymatic flux through glycolysis and gluconeo-
genesis, summarized on the right, is likely to be the critical mechanism for rapid regulation of this process.
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dered in recent years.
Fructose-1,6-Bisphosphatase
Fructose-1,6-bisphosphatase (FBP) catalyzes the penultimate
step in gluconeogenesis, converting fructose-1,6-bisphosphate
(F1,6BP) to fructose-6-phosphate (Figure 2). This step is neces-
sary for the incorporation of three-carbon substrates into
glucose (Pilkis and Claus, 1991) and makes FBP an attractive
target for drug development, given that glycerol gluconeogen-
esis is increased in diabetes. Indeed, genetic mutations and
pharmacological inhibition of FBP in rats and humans (Gumbiner
et al., 2009) demonstrate its regulatory role in HGP. Feedback
inhibition by fructose-2,6-bisphosphate (F2,6BP) and AMP
reduces flux through FBP, while glucagon stimulation of
cAMP/PKA rapidly reduces intracellular F2,6BP by favoring the
phosphatase activity of 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase and relieves FBP inhibition to drive gluco-
neogenesis (Pilkis and Claus, 1991). Accordingly, raising hepatic
F2,6BP levels improves insulin sensitivity and lowers glycemia in
mice, while reduction of F2,6BP levels has the opposite effect
(Wu et al., 2006). In addition, FBP activation depletes its
substrate F1,6BP—an allosteric activator of the glycolytic
enzyme liver-type pyruvate kinase (PK). PK—the opposing en-
zyme to PCK1 in the phosphoenolpyruvate/pyruvate cycle—isalso inhibited by glucagon and ATP (Pilkis and Claus, 1991).
Thus, glucagon simultaneously activates FBP and inhibits PK
by phosphorylation of both enzymes and by a coordinate
increase in F1,6BP and decrease in F2,6BP, driving glucose
formation. Moreover, AMP and ATP levels directly regulate glu-
coneogenic and glycolytic enzymes, thus affecting the balance
between glucose storage/oxidation and production.
Pyruvate Dehydrogenase Kinase
The pyruvate dehydrogenase complex (PDC) converts pyruvate
to acetyl-CoA, committing the substrate to cellular respiration.
PDC is phosphorylated and inhibited by pyruvate dehydroge-
nase kinase (PDK) and dephosphorylated and activated by pyru-
vate dehydrogenase phosphatase. PDK is in turn activated by
the products of PDC, acetyl-CoA, and NADH (Figure 2). Among
the four PDK isoforms, PDK2 and PDK4 are induced by fasting
and inhibited by insulin. PDK inhibits PDC during fasting, sparing
pyruvate for gluconeogenesis. Accordingly, Pdk4 knockout mice
show fasting hypoglycemia, secondary to increased systemic
glucose oxidation and decreased gluconeogenic substrate
delivery to the liver (Jeoung et al., 2006). Pharmacological inhib-
itors of PDK reduce glycemia in diabetic rodents (Mayers et al.,
2005), but the underlying mechanism of increasing glucose
oxidation at the expense of fatty acid oxidation suggests a poten-
tial risk for hepatosteatosis.Cell Metabolism 14, July 6, 2011 ª2011 Elsevier Inc. 11
Cell Metabolism
ReviewTranscriptional Regulation of HGP by Insulin,
cAMP, and Somatostatin
Forkhead-O Transcription Factors
The identification of the forkhead transcription factor daf-16 as
effector of insulin receptor signaling in C. elegans led to the test-
able hypothesis that its mammalian ortholog, FoxO1, was the
long-sought hormone-regulated transcription factor that inte-
grated cell surface receptor signaling with HGP (Accili and Ar-
den, 2004). FoxO proteins meet the ‘‘Exton and Park’’ criteria
for putative mediators of hormonal HGP. cAMP promotes
FoxO nuclear retention and dephosphorylation, whereas insulin
at low concentrations promptly inactivates FoxO by driving its
nuclear exclusion via Akt-dependent phosphorylation (Nakae
et al., 2001). The main FoxO target, G6pc is key to physiologic
control of HGP. In dogs subjected to physiologic hyperinsuline-
mia, FoxO1 phosphorylation parallels inhibition of G6pc
messenger RNA (mRNA) and suppression of glycogenolysis
(Ramnanan et al., 2010). FoxO1 loss of function in liver reduces
HGP by half by decreasing glycogenolysis, gluconeogenesis,
and glucose cycling and results in neonatal and starvation-
induced hypoglycemia (Matsumoto et al., 2007), whereas its
gain of function prevents hormonal regulation of HGP (Nakae
et al., 2002). The extent to which residual HGP in FoxO1
knockout mice reflects nontranscriptional effects of hormones
on glucose flux, indirect regulation of HGP (e.g., through the
central nervous system [CNS]), or additional hepatic transcrip-
tion factors (e.g., CRTC2) is at present unknown. When all three
Foxo genes (1, 3a, and 4) are ablated from mouse liver, fasting
glycemia is extremely low (30 mg/dl), but decreases in G6pc
are moderate, indicating that additional target genes and mech-
anisms contribute to FoxO regulation of HGP (Haeusler et al.,
2010) (Figure 2).
Insulin Signaling Pathways to HGP
The Irs/PI-3K/Akt/FoxO pathway is critical for insulin regulation
of hepatic glucose metabolism (Dong et al., 2008). Additional
serine/threonine kinases, such as atypical PKCs and salt-induc-
ible kinases (SIK1 and 2), have been proposed to regulate HGP.
But atypical PKC knockout mice have normal HGP (Matsumoto
et al., 2003), amidst lingering controversy on PKC activation by
insulin. The involvement of SIK1 and 2 is indirect: SIK1 is regu-
lated transcriptionally (Koo et al., 2005), whereas SIK2 is regu-
lated via Akt-dependent phosphorylation (Dentin et al., 2007)
and can thus likely be subsumed under the Akt pathway. Signal
transducer and activator of transcription 3 (STAT3) is phosphor-
ylated in response to insulin, and its ablation increases HGP
(Inoue et al., 2004a). However, this appears to be an indirect
effect of insulin, as will be discussed in the section on liver/brain
interactions.
Attempts to identify Akt modulators that affect HGP have been
marred by confusing results. Tribbles homolog 3 (Trb3) was iden-
tified as an inhibitory pseudosubstrate of Akt, whose gain of
function induced insulin resistance and raised glycemia in mice
(Du et al., 2003). But loss-of-function data are generally inconsis-
tent with a role of Trb3 in insulin action or HGP: whereas one
report showed improved glucose tolerance after small interfering
RNA-mediated Trb3 knockdown (Koo et al., 2004), Akt signaling
and hepatic glucosemetabolismwere normal in different models
of Trb3 loss of function in rodents (Okamoto et al., 2007).
A similar fate befell adaptor protein APPL1: originally shown to12 Cell Metabolism 14, July 6, 2011 ª2011 Elsevier Inc.prevent the interaction of Trb3 with Akt and increase HGP inhibi-
tion by insulin, its knockout had no effect on glucose tolerance
and insulin sensitivity (Tan et al., 2010). In summary, it appears
that the rise of HGP in diabetes cannot be explained by postre-
ceptor mechanisms of insulin resistance and requires decreased
insulin receptor number and/or activity as the sine qua non of
reduced insulin signaling (Lauro et al., 1998).
Peroxisome Proliferator-Activated Receptor g
Coactivator-1a
Peroxisome proliferator-activated receptor g coactivator-1a
(PGC-1a) is induced by fasting and promotes transcription of
glucogenic enzymes and mitochondrial proteins (Yoon et al.,
2001). FoxO1 is the obligate partner for the former, but not for
the latter effect (Matsumoto et al., 2007). The FoxO1 requirement
explains why knockout of Pgc1a has modest effects on HGP
(Lin et al., 2004). Substrate flux analysis by MR spectroscopy
shows that PGC-1a affects HGP by promoting mitochondrial
biogenesis and oxidative metabolism (Burgess et al., 2006).
The extent and relative role of direct regulation of PGC-1a by
insulin is disputed: one report indicates that insulin decreases
Pgc1a mRNA (Herzig et al., 2001), while another shows that it
promotes PGC-1a phosphorylation (Li et al., 2007). The meta-
bolic phenotype of liver-specific PGC-1a knockouts has not
been reported to date.
cAMP Response Element-Binding Protein
Transcription factor cAMP response element-binding protein
(CREB) belongs to a family of stress-activated DNA binding
proteins withmultifaceted functions. Hepatic CREB is phosphor-
ylated in response to glucagon, catecholamines, and insulin
(Koo et al., 2005) and binds to cis-acting cAMP response
elements on target promoters. Phosphorylated CREB acts as
a scaffold for coregulators such as CBP, p300, and CREB-regu-
lated transcription coactivator 2 (CRTC2) that activate gluconeo-
genic genes (Koo et al., 2005). A dominant-negative CREB
mutant causes fasting hypoglycemia that can be rescued by
PGC-1a overexpression (Herzig et al., 2001). Acute CREB
knockdown in liver reduced glycemia and improved insulin
sensitivity in diabetic mice and rats (Erion et al., 2009a), but to
date we lack amodel of liver-specific CREB knockout that would
allow us to parse its complex effects. The mechanism by which
CREB affects HGP remains unclear, given that the competing
hormones insulin and glucagon have similar effects on CREB
phosphorylation.
CREB-Regulated Transcriptional Coactivator 2
CREB-regulated transcriptional coactivator 2 (CRTC2; also
known as TORC2, not to be confused with the target of rapamy-
cin complex 2) is a CREB coactivator that confers hormone
regulation on HGP (Koo et al., 2005). During fasting, CRTC2 is
dephosphorylated, allowing its nuclear translocation. Nuclear
CRTC2 binds to CREB and recruits CBP and p300 to activate
Pck1, G6pc, and Pgc1a transcription (Koo et al., 2005). Insulin
triggers CRTC2 phosphorylation via SIK2, promoting its nuclear
exclusion and proteosomal degradation (Dentin et al., 2007).
Two CRTC2 knockout alleles have been made to test its role
in vivo: a liver-specific knockout has no effect on HGP or glyce-
mia (Le Lay et al., 2009), while a ubiquitous knockout lowers fast-
ing glycemia by25% aswell as Pck1 andG6pc levels, together
with a 2-fold reduction of glucose output from isolated hepato-
cytes, but HGP was not measured in vivo (Wang et al., 2010).
Cell Metabolism
ReviewThe reasons for this discrepancy are unclear and will have to be
addressed if a consensus on the role of CRTC2 in HGP is to be
reached.
Glucocorticoids
Glucocorticoids (GCs) drive HGP directly by transcriptional
induction of Pck1 and tyrosine aminotransferase (Tat), and indi-
rectly through their actions in muscle and adipose tissue to
promote amino acid and glycerol flux to the liver, and by
decreasing insulin production in pancreatic b cells. Pharmaco-
logical inhibition of the enzyme required to generate bioactive
corticosterone, 11b-hydroxysteroid dehydrogenase type 1
improves glucose control in type 2 diabetic patients (Rosenstock
et al., 2010). However, regulation of glycogenolysis in primary
hepatocytes doesn’t require GC (Matsumoto et al., 2007), indi-
cating that these hormones participate primarily in the regulation
of HGP by stress, rather than by fasting and feeding.
GC action on Pck1 and Tat transcription is mediated through
ligand-induced binding of the nuclear glucocorticoid receptor
(GR, encoded by Nr3c1) to GC response elements. Liver-
specific GR knockout mice are euglycemic in physiologic condi-
tions but are prone to hypoglycemia during starvation (Opherk
et al., 2004). Knockdown of liver and adipose GR reduced
HGP and glycemia in diabetic rodents, as did a liver-selective
synthetic GR antagonist (Watts et al., 2005). These studies
indicate that hepatic GC/GR signaling is essential for the
stress-induced glycemic response. Efforts to leverage the
eminent pharmacological tractability of GCs to modulate HGP
are limited by potential side effects of GC blockade on the
hypothalamic-pituitary-adrenal axis, and by lingering uncer-
tainty on the contribution of GC excess to the pathogenesis of
human diabetes.
NR4As
Transcription of the three orphan nuclear receptors of the NR4A
family (Nurr77, Nurr1, and NOR-1, encoded byNr4a1, 2, and 3) is
rapidly induced by glucagon or fasting in liver (Pei et al., 2006).
Overexpression of each NR4A isoform in cultured hepatocytes
activates G6pc, Fbp, and enolase. Accordingly, a pan-NR4A
dominant negative mutant lowered HGP, while Nurr77 overex-
pression in liver increased it (Pei et al., 2006). But whole-body
Nurr77 knockout also increased HGP (Chao et al., 2009). It
should be noted that glucagon promotes HGP without stimu-
lating new protein synthesis (Exton and Park, 1967), making it
unlikely that NR4As—whose induction requires de novo
synthesis—are physiologic mediators of glucagon’s effects
on HGP.
Adenosine 50-Monophosphate-Activated Protein Kinase
Adenosine 50-monophosphate-activated protein kinase (AMPK)
is a cellular sensor of energy levels. Activated by AMP- or
Ca2+-dependent phosphorylation through LKB1 and CaMKKb,
respectively, AMPK generates ATP by increasing fatty acid
oxidation and reducing ATP hydrolysis through decreased lipo-
genesis and glucogenesis (Zhang et al., 2009). Glucagon can
also activate AMPK, but it fails to do so in liver-specific Pck1
knockout mice (Berglund et al., 2009), suggesting that its effects
on AMPK are mediated by cellular ATP depletion through gluco-
neogenesis. Whole-body knockout of AMPKa2—the predomi-
nant catalytic subunit in liver—did not affect HGP, whereas
liver-specific AMPKa2 knockout caused a modest increase in
basal HGP (Andreelli et al., 2006). The multiplicity of AMPK func-tions complicates the dissection of its upstream regulators and
downstream targets.
Upstream. AMPK activators, 5-aminoimidazole-4-carboxa-
mide riboside (AICAR), metformin, A-769662, and adiponectin
suppress HGP (Zhang et al., 2009). However, these effects are
preserved in mice lacking AMPK (Foretz et al., 2010), indicating
that they are mediated through different mechanisms, e.g.,
cellular respiration. Presently, it’s unknown whether the effect
of the adipokine resistin on HGP is mediated through its ability
to regulate AMPK. Inactivation of the AMPK kinase LKB1
increases glycemia and causes nuclear accumulation of
CRTC2 (Shaw et al., 2005), but HGP was not measured in this
study, and individual contributions of LKB1 substrates—
AMPK, SIK1-2, and MAP/microtubule affinity-regulating kinase
2 (MARK2)—to this phenotype haven’t been determined.
Downstream. Despite the important role of FoxO in HGP, its
regulation by AMPK has not been examined extensively;
in vitro data suggest that AMPK promotes FoxO3a activity (Greer
et al., 2007). More efforts have gone into demonstrating the role
of AMPK in CRTC2 phosphorylation. The latter can be blocked
by AMPK and related kinases (SIK1-2, MARK2) (Koo et al.,
2005) and becomes impaired when AMPKa1 and a2 are ablated
in liver. The meaning of this observation is mysterious, as these
mice have normal HGP (Foretz et al., 2010). The contribution of
additional AMPK substrates to HGP is thus far based on
in vitro data and awaits experimental confirmation in vivo.
Collectively, these data suggest that AMPK and related kinases
can restrain gluconeogenesis during extreme energy deficit or
diabetes, but not under physiological conditions.
Regulation of HGP by Bile Acid Signaling
Farnesoid X Receptor
Bile acids (BAs) inhibit HGP, and BA sequestrants decrease
glycemia and improve dyslipidemia in type 2 diabetics. BAs
bind nuclear receptor farnesoid X receptor (FXR) and lower
glucose by hepatic and extra-hepatic mechanisms. The BA
cholic acid inhibits Pck1 andG6pc via FXR-dependent induction
of small heterodimer partner (SHP) (Ma et al., 2006). Phenotyping
of FXR knockouts has yielded different but not irreconcilable
results, with one study showing transient fasting hypoglycemia
due to defective glycogen turnover (Cariou et al., 2005), and
another one showing hyperglycemia secondary to hepatic and
muscle insulin resistance (Ma et al., 2006). These observations
are likely to reflect multiple glucoregulatory pathways affected
by FXR deficiency, such as BA biosynthesis, which can poten-
tially affect incretin secretion (Thomas et al., 2009), and
FGF15/19 regulation as discussed below.
The Corepressor SHP
The FXR target gene Shp (Nr0b2) encodes an atypical orphan
nuclear receptor that lacks a DNA binding domain and represses
expression of genes implicated in HGP, including G6pc, Pck1,
and Pdk4 (Kim et al., 2008). Shp knockout mice show modest
fed and fasted hyperglycemia and resistance to BA inhibition
of Pck1 and G6pc (Ma et al., 2006). Conversely, SHP overex-
pression in liver reducedPck1 andG6pc expression and lowered
glycemia in diabetic mice (Kim et al., 2008).
Fibroblast Growth Factor 15/19
Postprandial release of BA activates expression of FGF15 (19 in
rodents) in the small intestine through FXR (Inagaki et al., 2005).Cell Metabolism 14, July 6, 2011 ª2011 Elsevier Inc. 13
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synthesis. Interestingly, these actions appear to be mediated
by ERK rather than Akt (Kir et al., 2011). However, FGF15 can
also activate Akt and inhibit Pck1 through the canonical FoxO1
pathway (Shin and Osborne, 2009). The insulin-like actions of
FGF15/19 provide a potential alternative pathway to control
HGP.
Orphan Regulators of HGP
CCAAT/Enhancer-Binding Protein a and b
Ablation of transcription factor CCAAT/enhancer-binding protein
a (C/EBPa) causes lethal neonatal hypoglycemia due to delayed
onset of G6pc and Pck1 expression (Wang et al., 1995). But in
the adult animal, data are discordant, with some loss-of-function
studies showing significant hypoglycemia and liver damage (Lee
et al., 1997), while others showed no effect on HGP (Inoue et al.,
2004b). Regardless of this discrepancy, there is no evidence of
C/EBPa regulation by hormone signaling. It’s worth noting that
C/EBPa coordinately controls glycogen synthase, Pck1, and
G6pc, providing a potential mechanism for hepatic autoregula-
tion. C/EBPb deletion in mice also causes hypoglycemia in
neonates and in fasted adults. This phenotype illustrates the
difficulties of extrapolating from effects on gene expression to
effects on HGP. In fact, while C/EBPb gain-of-function activates
Pck1 and G6pc in hepatocytes, its loss of function lowers HGP
by decreasing cAMP production (Croniger et al., 2001), and
not by affecting gene expression (Figure 2).
Steroid Receptor Coactivator Family
Histone acetyltransferases steroid receptor coactivator 1 (SRC-
1), 2, and 3 coactivate several nuclear receptors and transcrip-
tion factors. Hepatic expression of SRC-1 and SRC-3, but not
SRC-2, is induced by fasting. Despite apparent functional
promiscuity in cell culture experiments, different SRC knockout
mice have distinct phenotypes. Ubiquitous and liver-specific
Src1 knockout mice are hypoglycemic due to reduced HGP,
associated with decreased expression of Pck1, Fbp, and pyru-
vate carboxylase, but not G6pc (Louet et al., 2010). Mechanistic
studies revealed that SRC-1 coactivates C/EBPa and PGC-1a
and is required for Cebpa and Foxo1 expression in liver (Louet
et al., 2010), consistent with a role in controlling gluconeogenesis
during the fed-to-fasting transition. SRC-2 regulates G6pc
expression by coactivating retinoid-related orphan receptor a,
and hepatic SRC-2 loss of function led to fasting hypoglycemia,
owing to low G6pc expression, and potential secondary effects
of hepatic BA accumulation due to defective secretion into the
gut (Chopra et al., 2011). The role of SRC-3 in HGP has not
been determined. To establish that these interesting observa-
tions have physiological relevance, it will be necessary to study
whether hormones and nutrients regulate the activity of these
coactivators.
Sirtuin-1
The NAD+-dependent protein deacetylase Sirt1 can activate
HGP by deacetylating its substrates PGC-1a, FoxO1, STAT3,
and FXR (Schwer and Verdin, 2008). Changes of hepatic glucose
metabolism in liver-specific Sirt1 knockouts are unremarkable
(Chen et al., 2008), but this might reflect opposing effects of
other Sirt1-dependent processes, such as CRTC2 degradation
(Liu et al., 2008), SHP induction (Wei et al., 2011), and AMPK acti-
vation (Hou et al., 2008). In fact, Sirt1 ablation lowered HGP in14 Cell Metabolism 14, July 6, 2011 ª2011 Elsevier Inc.insulin-resistant mice lacking both Irs1 and Irs2, restoring the
postprandial suppression of Pgc1a and Pck1. And acute knock-
down of Sirt1 in liver of rodents (Erion et al., 2009b) reduced fast-
ing glycemia, decreased Pck1, G6pc, and Fbp, and increased
glucokinase. Conversely, Sirt1 overexpression in liver increased
gluconeogenic gene expression during fasting (Rodgers and
Puigserver, 2007), but ubiquitous overexpression reduced fast-
ing glycemia and improved glucose tolerance in obese mice,
despite constitutive deacetylation of PGC-1a and FoxO1 in liver
(Banks et al., 2008), owing possibly to decreased hepatosteato-
sis and increased adiponectin levels. Under conditions of
nutrient excess, these indirect pathways might trump Sirt1’s
direct gluconeogenic effects.
Circadian Pacemakers
Circadian oscillations in glucose and lipid metabolism are well
documented and disruptions of such temporal regulation are
associated with metabolic diseases. Core clock components
regulate rhythmicity and amplitude of HGP, including Clock,
Bmal1, Period2, Cryptochrome (Cry) 1 and 2, and Rev-Erba
(Bass and Takahashi, 2010). The liver clock is regulated by
cellular energy sensors such as AMPK, which modulates Cry1
degradation (Lamia et al., 2009), and NAD+, which regulates
Sirt1- and poly [ADP-ribose] polymerase-1-dependent post-
translational modifications of clock components (Nakahata
et al., 2008). PGC-1a and GR (So et al., 2009) can also modulate
components of the liver clock. Additional work is necessary to
dissect the significance of these pathways in diabetes pathogen-
esis and treatment.
Direct versus Indirect Mechanisms
Central Nervous System Effects on HGP in Rodents
In rodents, the direct effects of insulin in liver are necessary, but
not sufficient to inhibit HGP (Okamoto et al., 2005). Insulin
receptor signaling in hypothalamic neurons affects HGP by acti-
vating KATP channels and suppressing flux through G6PC, but
not PCK1 (Obici and Rossetti, 2003). The site of insulin action
includes orexigenic (appetite-promoting) NPY/AgRP neurons
(Ko¨nner et al., 2007) and anorexigenic POMC neurons (Lin
et al., 2010). The mechanism may also involve activation of
STAT3 via IL-6 signaling (Inoue et al., 2006), providing a potential
link with inflammatory changes that are associated with insulin
resistance.
Whether neuronal control of HGP is unique to rodents remains
disputed. HGP rates in rodents are 10-fold higher than
humans, indicating that potential CNS effects might go unde-
tected in human studies. Direct delivery of insulin to the CNS
of dogs doesn’t affect HGP, raising the possibility that the
‘‘CNS effect’’ on HGP reflect a failure to properly replace basal
portal insulin levels during glucose clamps (Edgerton et al.,
2006). However, it should be noted that insulin fails to suppress
HGP in mice lacking peripheral but not hepatic insulin receptors.
In these mice, the portohepatic insulin gradient is probably
ablated by the lack of receptor-mediated insulin clearance in
tissues exposed to the systemic circulation, and portal
insulin levels should suffice to inhibit HGP—but don’t (Okamoto
et al., 2005).
Free Fatty Acids, Adipokines, and HGP
FFA uptake into the liver is thought to impair HGP regulation by
insulin (Lewis et al., 1997). However, the rise of FFAs in insulin
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Reviewresistance antedates fasting hyperglycemia—the hallmark of
increased HGP. And the onset of hyperglycemia is not associ-
ated with worsening FFA profiles. Furthermore, manipulations
of circulating F elicit similar changes in gluconeogenesis in
type 2 diabetics and nondiabetic subjects (Boden et al., 2001).
In mice lacking hepatocyte insulin receptors, acute lowering of
FFAs fails to suppress HGP (Fisher and Kahn, 2003). Therefore,
FFAs likely contribute to render HGP refractory to insulin but are
unlikely to be the inciting factor. Adding to the complexity of this
signaling mechanism, hypothalamic sensing of circulating FFAs
regulates HGP, and may counteract the direct effect of FFAs on
hepatocytes (Lam et al., 2005). Whether FFAs are the bellwether
of other adipocyte secretory products that impair insulin action
on HGP remains controversial. In vivo regulation of leptin and
adiponectin by insulin requires prolonged incubations. Thus,
neither is likely to contribute to the rapid hormonal regulation
of HGP, but they might contribute to setting a basal HGP tone.
Renal and Intestinal Gluconeogenesis
Renal epithelial cells produce glucose through a process regu-
lated by both insulin and pH. Cultured renal epithelial cells lose
the ability to respond to insulin, which can be restored by recon-
stituting FoxO1 (Nakae et al., 2001). The small intestine also
expresses G6pc and makes a contribution to systemic glucose
production that may become more significant in starvation and
diabetes. Intestinal gluconeogenesis has been implicated in
nutrient sensing in the portal vein (Troy et al., 2008). These obser-
vations need to be interpreted with caution because of the tech-
nical challenges in accurately measuring glucose production in
tissues with highly active glucose utilization such as kidney
and intestine.
Controversial Areas
Flux Control versus Gene Transcription
As indicated, a creative tension exists between the physiolo-
gists, who never fail to remind us that flux control trumps tran-
scriptional control of HGP, and the cell/molecular biologists,
who have been tenaciously chasing hormone-regulated
transcription factors as the holy grail of HGP. Based on the
data reviewed here, the truth appears to lie somewhere in
between: in vivo, it takes30 min to detect effects on glycogen-
olysis and gluconeogenesis, and while the latter are unrelated to
changes in Pck1 mRNA—let alone protein—the former show
a striking correlation with G6pcmRNA and FoxO1 phosphoryla-
tion (Ramnanan et al., 2010). Hence, we propose that flux control
is important in the first 30 min but that gene transcription kicks in
earlier than formerly surmised.
How Many Genes Mediate Hormonal Effects on HGP?
HGP is a complex and genetically heterogeneous process that
cannot be subsumed under a single mechanism. Nonetheless,
as illustrated by the litany of ‘‘buts,’’ ‘‘unclears,’’ and
‘‘unknowns’’ that graces this overview, most of the genes
proposed to play a role in this process fail one or more tests of
physiologic relevance. Among the reasons for this discrepancy
are the following: (1) Obliviousness to—and, for younger
researchers, unawareness of—the ‘‘Exton and Park’’ criteria.
(2) Variations of mRNAs encoding glucogenic enzymes,
let alone changes in reporter gene activities in hepatoma cells,
do not portend effects on HGP—the latter should be tested
directly. (3) Genetic ablation experiments resulting in fastinghypoglycemia don’t necessarily indicate a physiologic role in
hormonal regulation of HGP, given the latter’s redundancy. (4)
Gain-of-function experiments with transcription factors and co-
activators should be interpreted cautiously, as they are espe-
cially prone to artifacts. (5) Physiologically relevant conclusions
on the role of any given gene product should be supported by
both acute and chronicmanipulations in vivo. Acute transduction
of the liver with DNA- or RNA-based reagents by direct delivery,
while expeditious, often results in hepatocyte damage, itself
a regulator of HGP. As a result, interpretation of such data is
problematic. (6) Conversely, compensatory mechanisms (e.g.,
glucose cycling) may obfuscate the interpretation of gene knock-
outs. A useful approach in this regard is to study induction of
HGP at birth, as it first acquires hormone responsiveness (Girard
et al., 1992). (7) Many genes affect HGP indirectly, through
effects on hepatocyte function or intercellular communication
that are not involved in physiologic hormonal or nutrient regula-
tion; to determine their relevance to physiologic conditions and
disease states, it’s helpful to study their posttranslational regula-
tion in response to insulin and glucagon.
Gluconeogenesis and Pck1
Recent studies have led to a reassessment of the role of PCK1 as
rate-limiting enzyme in gluconeogenesis. Liver-specific Pck1
knockouts show a blockade of lactate and amino acid-derived
gluconeogenesis but maintain normal fasting glycemia, possibly
owing to increased gluconeogenesis from glycerol and reduced
glucose utilization (She et al., 2003). Ex vivo studies in mouse
livers with various levels of Pck1 ablation show a tight correlation
between PCK1 activity and TCA cycle flux, but weak control by
PCK1 over gluconeogenic capacity (Burgess et al., 2007). The
level of HGP regulation exerted through Pck1 transcription
in vivo is also modest, as gluconeogenesis can be suppressed
without changes in Pck1 expression in dogs (Ramnanan et al.,
2010), and liver biopsies from patients with type 2 diabetes fail
to demonstrate changes in Pck1 (Samuel et al., 2009). In vitro,
PCK1 can be inhibited by acetylation independent of changes
in protein levels (Lin et al., 2009), but the physiological signifi-
cance of this finding in liver metabolism hasn’t been determined.
Therapeutic Implications
How Does Metformin Work?
Several explanations for the effect of metformin to decrease
HGP have been set forth. The original hypothesis, that it does
so through activation of AMPK, has not been borne out by
genetic ablation of AMPK or its kinase LKB1, which, if anything,
sensitizes to metformin action on plasma glucose levels (Foretz
et al., 2010). Another study found that metformin was unable to
lower glycemia in liver LKB1-deficient mice, but this study didn’t
measure HGP (Shaw et al., 2005). Metformin reduces cellular
respiration in hepatocytes by inhibiting mitochondrial respiratory
chain complex I (El-Mir et al., 2000) and might thus blunt gluco-
neogenesis by reducing intracellular ATP. Interestingly, thiazoli-
dinediones and berberine are also mild inhibitors of respiratory
chain complex I (Turner et al., 2008). Other potential mediators
include elevations in AMP/ATP or NAD+/NADH ratios or reactive
nitrogen species (Fujita et al., 2010). The alternative explanation
that metformin decreases HGP via CBP phosphorylation by
PKCl, leading to decreased CREB/CRTC2 complex formation
(He et al., 2009), is unlikely considering the lack of effect onCell Metabolism 14, July 6, 2011 ª2011 Elsevier Inc. 15
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moto et al., 2003). Metformin has been shown to decrease
mRNA levels of transcription factor KLF-15, whose targets
includeG6pc andPck1 (Takashima et al., 2010), but the signaling
pathways by which metformin regulates gene expression are
unknown. In sum, it’s unlikely that metformin has an obligate
target. It’s more likely to act by lowering ATP levels, with pleio-
tropic consequences. The role of metformin transporters and
their complex genetic variation in determining metformin sensi-
tivity and failure remains underscrutinized.
Future Prospects
Is HGP inhibition the right approach to diabetes treatment?
Arguably, increased HGP is a ‘‘late’’ defect in disease progres-
sion, and it’s conceivable that preventive treatments (for
example, increasing glucose disposal or enhancing b cell func-
tion) will offset the need to intervene on this aspect of liver
dysfunction in diabetes. On the other hand, other pathogenetic
mechanisms (increased liver fat content and secretion of
VLDL-rich lipoproteins) will continue to require targeting the liver
in diabetes (Kim-Muller and Accili, 2011). Thus, we are unlikely to
write off the liver as a site of action of antidiabetic medications
any time soon. Among the mechanisms that have been explored
to sensitize the liver to insulin, the key obstacle has been the
potential for hypoglycemia, an inevitable concern with drugs
that concurrently inhibit HGP and enhance glucose disposal.
As glucagon levels are inappropriately elevated in diabetes,
inhibition of the glucagon receptor pathway is an attractive ther-
apeutic path. Acute inactivation of the glucagon receptor (GcgR)
lowers glucose in diabetic mice, while GcgR knockout mice are
hypoglycemic and resistant to STZ-induced diabetes (Conarello
et al., 2007). Inhibitors of glucagon/GcgR action have shown
promise in diabetes treatment, but their long-term impact on lipid
and amino acid metabolism is yet unknown.
Sirt1 activators lower glycemia in diabetic rodents but are
tainted by controversies over their bona fide Sirt1 activation
and in vivo efficacy (Pacholec et al., 2010). Activators of the
xenobiotic receptor, constitutive androstane receptor (CAR),
lower hyperglycemia and body weight in mice (Dong et al.,
2009), but the role of CAR in drug metabolism and thyroid
hormone metabolism may hamper their utility as antidiabetic
compounds. Inhibition of PDK4 or FBPase has a long and
checkered history dating back to dichloroacetate. It remains
challenging to fine-tune glucose flux without causing irreversible
hypoglycemia or contributing to lactic acidosis. Buoyed by new
injection devices and a broader acceptance of parenteral treat-
ments, peptide mimetics of insulin action, or ‘‘selective insulin
sensitizers’’ deserve scrutiny (Kim-Muller and Accili, 2011).
Conclusions
Key biochemical, cellular, and integrated physiological mecha-
nisms by which hormones regulate HGP have been clarified.
But few players thus identified are tractable drug targets. There-
fore, given its efficacy, tolerability and inexpensiveness, metfor-
min is likely to remain the mainstay of therapy, despite its limita-
tions. New antidiabetic agents should therefore either reduce
HGP by a mechanism distinct from metformin’s, or target
different aspects of diabetes pathophysiology (impaired glucose
uptake, excessive lipolysis, increased tissue fat content, b cell
dysfunction, elevated atherogenic lipoproteins), or improve16 Cell Metabolism 14, July 6, 2011 ª2011 Elsevier Inc.safety vis-a`-vis lactic acidosis or use in renal failure, or outper-
form metformin’s durability. The studies reviewed here will help
chart the way ahead.
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